Stockscreener 앱 받기
82.11
0.15%
0.12
시간 외 거래:
82.11
전일 마감가:
$81.99
열려 있는:
$82.9
하루 거래량:
110.29K
Relative Volume:
0.49
시가총액:
$1.19B
수익:
$1.80M
순이익/손실:
$1.76B
주가수익비율:
0.6919
EPS:
118.674
순현금흐름:
$-149.23M
1주 성능:
+0.71%
1개월 성능:
+8.12%
6개월 성능:
+274.59%
1년 성능:
+539.98%
1일 변동 폭
$79.36
$83.84
1주일 범위
$77.24
$88.72
52주 변동 폭
$10.80
$94.56
인히브릭스 Stock (INBX) Company Profile
명칭
Inhibrx Biosciences Inc
전화
(858) 795-4220
주소
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
82.11 | 1.19B | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
인히브릭스 Stock (INBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-23 | 개시 | JMP Securities | Mkt Perform |
| 2024-01-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | 개시 | SMBC Nikko | Outperform |
| 2021-09-21 | 개시 | JMP Securities | Mkt Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Evercore ISI | Outperform |
모두보기
인히브릭스 주식(INBX)의 최신 뉴스
Fund Flows: Whats the beta of Inhibrx Biosciences Inc stock2025 Market WrapUp & Reliable Breakout Forecasts - baoquankhu1.vn
How Inhibrx Biosciences Inc Com (INBX) Affects Rotational Strategy Timing - Stock Traders Daily
Does Inhibrx Biosciences Inc have strong EBITDA marginsJuly 2025 Pullbacks & Smart Money Movement Alerts - baoquankhu1.vn
Big Picture: Is Inhibrx Biosciences Inc stock undervalued right nowM&A Rumor & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 10.2%Still a Buy? - MarketBeat
Commit To Purchase Inhibrx Biosciences At $50, Earn 16.7% Annualized Using Options - Nasdaq
Insider Trends: Whats the MACD signal for Maris Tech Ltd Equity WarrantMarket Activity Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
(INBX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Inhibrx Biosciences Reports Promising Q3 2025 Results - MSN
S P Trends: Whats the outlook for SAIAs sectorDay Trade & High Accuracy Trade Alerts - baoquankhu1.vn
Aug Highlights: Is BILI benefiting from interest rate changesDividend Hike & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Sell Signal: Is Gorilla Technology Group Inc trading at a discountJuly 2025 Decliners & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Fed Watch: Will Hennessy Advisors Inc stock hit new highs in YEARLong Setup & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Responsive Playbooks and the INBX Inflection - Stock Traders Daily
Short Interest in Inhibrx Biosciences, Inc. (NASDAQ:INBX) Rises By 63.1% - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Nasdaq Futures Science-Driven Path - Kalkine Media
Risk Hedge: Whats the beta of Inhibrx Biosciences Inc stockEarnings Miss & Fast Gain Swing Alerts - baoquankhu1.vn
Earnings Risk: Is Inhibrx Biosciences Inc stock a smart buy before Fed meetingJuly 2025 Highlights & Low Risk Profit Maximizing Plans - Bộ Nội Vụ
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 6.5%What's Next? - MarketBeat
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too (INBX) - Seeking Alpha
Is Inhibrx Biosciences Inc. stock attractive for passive investorsJuly 2025 Big Picture & Low Risk High Reward Trade Ideas - Улправда
Is Inhibrx Biosciences Inc. stock dividend yield sustainable2025 Biggest Moves & High Conviction Trade Alerts - Улправда
Can Inhibrx Biosciences Inc. stock deliver surprise earnings beatTake Profit & AI Powered Buy and Sell Recommendations - Улправда
Understanding the Setup: (INBX) and Scalable Risk - Stock Traders Daily
What drives Inhibrx Biosciences Inc stock priceEarnings Per Share Trends & Missed Nvidia? Don’t Miss This One - Early Times
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Sees Large Decline in Short Interest - MarketBeat
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts - Insider Monkey
Inhibrx Biosciences (NASDAQ:INBX) Trading Up 7.2% – Here’s Why - Defense World
How (INBX) Movements Inform Risk Allocation Models - Stock Traders Daily
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 7.2%Should You Buy? - MarketBeat
Why Inhibrx's Recent Strength May Not Be Built to LastInhibrx Biosciences (NASDAQ:INBX) - Benzinga
Inhibrx Biosciences (NASDAQ:INBX) Shares Down 7.9%Here's Why - MarketBeat
Is Inhibrx Biosciences (NASDAQ:INBX) A Risky Investment? - 富途牛牛
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 1-Year HighHere's Why - MarketBeat
Inhibrx Biosciences, Inc.(NasdaqGS:INBX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Why Inhibrx Biosciences Inc. stock could rally in 2025July 2025 Market Mood & Fast Gain Stock Tips - Улправда
Is Inhibrx Biosciences Inc. stock trading at a premium valuation2025 Dividend Review & Low Risk Investment Opportunities - bolumsonucanavari.com
Buyout Rumor: How Inhibrx Biosciences Inc. stock benefits from tech adoptionWall Street Watch & High Yield Equity Trading Tips - ulpravda.ru
Can Inhibrx Biosciences Inc. stock withstand economic slowdownWeekly Trend Recap & Short-Term Trading Alerts - DonanımHaber
How Inhibrx Biosciences Inc. stock benefits from tech adoptionJuly 2025 Patterns & High Conviction Investment Ideas - Улправда
Will Inhibrx Biosciences Inc. stock deliver consistent dividends2025 Earnings Impact & Capital Efficient Trading Techniques - Улправда
Inhibrx (INBX): Assessing a Lofty Valuation After Fresh INBRX-106 and Ozekibart Milestone Updates - Yahoo Finance
Is Inhibrx Biosciences Stock Built to Withstand a Pullback? - Trefis
Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates - Sahm
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - The Malaysian Reserve
Citizens reiterates Market Perform rating on Inhibrx Biosciences stock citing limited data disclosures - Investing.com Canada
Inhibrx Biosciences, Inc provides progress updates on the Inbrx-106 program and the expansion cohorts of the Ozekibart (Inbrx-109) program - marketscreener.com
Inhibrx Biosciences Announced An Update On The INBRX-106 Phase 2/3 Clinical Trial In Combination With Keytruda; Inhibrx Expects To Complete Enrollment In The Phase 2 Portion Of The Trial During The First Quarter Of 2026 - Sahm
Inhibrx Biosciences Provides Updates on Clinical Trials - TradingView — Track All Markets
[8-K] Inhibrx Biosciences, Inc. Reports Material Event | INBX SEC FilingForm 8-K - Stock Titan
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 6.6%Here's Why - MarketBeat
인히브릭스 (INBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):